Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
21.13
-0.12 (-0.56%)
At close: Mar 16, 2026, 4:00 PM EDT
21.25
+0.12 (0.57%)
Pre-market: Mar 17, 2026, 9:13 AM EDT
Lyell Immunopharma Market Cap
Lyell Immunopharma has a market cap or net worth of $492.48 million as of March 17, 2026. Its market cap has increased by 137.15% in one year.
Market Cap
492.48M
Enterprise Value
287.18M
1-Year Change
137.15%
Ranking
Category
Stock Price
$21.13
Market Cap Chart
Since the IPO on June 17, 2021, Lyell Immunopharma's market cap has decreased from $4.13B to $492.48M, a decrease of -88.07%. That is a compound annual growth rate of -36.10%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 16, 2026 | 448.88M | -31.35% |
| Dec 31, 2025 | 653.89M | 249.70% |
| Dec 31, 2024 | 186.98M | -61.73% |
| Dec 29, 2023 | 488.63M | -43.52% |
| Dec 30, 2022 | 865.16M | -53.52% |
| Dec 31, 2021 | 1.86B | -54.91% |
| Jun 17, 2021 | 4.13B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Verastem | 510.32M |
| Contineum Therapeutics | 499.18M |
| Fulcrum Therapeutics | 495.51M |
| Prothena Corporation | 493.65M |
| Rigel Pharmaceuticals | 490.46M |
| Entrada Therapeutics | 487.74M |
| enGene Holdings | 484.33M |
| Atea Pharmaceuticals | 482.02M |